PHARMA NEWS, MULTICHANNEL & CROSSCHANNEL MAKETING
283.2K views | +16 today
Follow

How to achieve successful HCP behaviour change

From www.wearecouch.com

The application of existing and new theories, translating theory into real-world solutions, is key to sustainable HCP behaviour change.
No comment yet.

How pharma and patient advocacy groups can become in sync

From www.linkedin.com

At next month’s Patient Summit Europe (19-20 October, London) find out how you can be more than a trusted partner – get yourself on the same side as your patients, and deliver sophisticated advocacy that fights their cause.

Patient advocacy groups and pharma companies have the same ultimate goal – better health outcomes – but managing these relationships needs care on both sides.

To give you an insight into the level of discussion you can expect at the summit, we spoke with:
- Nisith Kumar, Director, Global Patient Affairs, Pfizer
- Ann Kwong, Founder and CEO, TREK Therapeutics
- Lynn Bartnicki, Patient advocate, Living Beyond Breast Cancer

Read the article ‘Dancing to the same tune?’ here: https://goo.gl/hgVVms
Kind regards,
Cintia Hernandez Marco

rob halkes's curator insight, September 13, 2017 8:27 AM

“Some drug companies are really focused on patients, and some don’t have a clue.” Lynn Bartnicki, patient advocate

- a quote from the report of Eyeforpharma.

Good to see some words from pharma and patient advocates published.

Even better to follow and read one of the many publications about the pharma and patient groups' relations: a trying but difficult engagement

You can look at the patient perspective in "pharma corporate reputations",

or overviews of the patient movement. A study about pharma and the connected patient. And above all: check your own credibility as a pharma company in the eyes of patients: your bespoke data on your company, for its different affiliations and therapy areas, based on 6 years of global data on corporate reputation in the perspective of patients and patient groups.

rob halkes's curator insight, September 13, 2017 8:41 AM

“Some drug companies are really focused on patients, and some don’t have a clue.” Lynn Bartnicki, patient advocate

- a quote from the report of Eyeforpharma.

Good to see some words from pharma and patient advocates published.

Even better to follow and read one of the many publications about the pharma and patient groups' relations: a trying but difficult engagement

You can look at the patient perspective in "pharma corporate reputations", or at overviews of the patient movement. 

A study about pharma and the connected patient. And above all: check your own credibility as a pharma company in the eyes of patients: your bespoke data on your company, for its different affiliations and therapy areas, based on 6 years of global data on corporate reputation in the perspective of patients and patient groups.

Un lab "100% dédié à l'e-santé" bientôt ouvert sur le campus de Sanofi

From www.ticpharma.com

PARIS (TICpharma) - Sanofi va ouvrir avant la fin de l'année sur son campus de Gentilly (Val-de-Marne) un laboratoire "100% dédié à l'e-santé" intitulé "39Bis", ont annoncé jeudi à la presse le directeur de Sanofi France, Guillaume Leroy, et la directrice de l'innovation, Isabelle Vitali.


No comment yet.

#Top 10 Pharma: Twitter Engagement Index - Listly

From list.ly

Oltre i follower .... l'Engagement Index.
It is calculated by a statistical analysis on engagement, reach, demographics, network and othe
No comment yet.

Lifetime Trends in Biopharmaceutical Innovation Recent Evidence and Implications

From www.imshealth.com

This report profiles the NASs launched in the U.S. over the past 20 years and measures the length of a molecule’s lifetime from patent filing to launch and eventual patent expiry. It also explores the significant variations in this lifetime when viewed by molecule characteristics such as therapy area, orphan drug status, and the type of companies involved in the development and marketing.

Take a look at some of the coverage from the event in The Scientist, American Journal of Managed Care, and The Pharma Letter.

rob halkes's curator insight, February 7, 2017 5:27 AM

Relevant Insights into the development in lifetime characteristics of biopharmaceutical substances: only relative few outliers that make a quick retunr about 1$ billion a year (within 5 years after launch) Modest levels of average return (less than $100 billion) a year for 62% of launches in the past 20 years. The commercial returns for a small number of outlier molecules areoutsized but rare, while a substantial number of molecules baing launches achive levels of commercial success that fall far below threshold levels of economic return.

Take a look at some of the coverage from the event in The Scientist, American Journal of Managed Care,
 

Moving Beyond the Pill in the Healthcare Sector - eMarketer

From www.emarketer.com

Mobile is encouraging healthy behavior

Pharmaceutical manufacturers, payers and healthcare providers (HCPs)—as well as a host of tech-focused newcomers—are exploring digital programs that complement standard therapies and hold promise to keep patients healthier and produce better outcomes. Known as “beyond-the-pill” or “around-the-pill” services, they have been a long time coming, and may finally be gaining traction, according to a new eMarketer report,“US Healthcare Beyond the Pill: Digital Tech and New Partnerships Bring New Life to the Industry” (eMarketer PRO customers only).

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the past several years, healthcare and pharma firms have been trying, with mixed success, to step up their beyond-the-pill programs. Early efforts included basic informational websites and simple apps designed to provide information about medical conditions and therapies.

“When the pharma industry first moved into digital technology, it was primarily in the marketing space, leveraging things like websites or HCP portals to share product information and to educate,” said Amy Landucci, head of digital medicine at Novartis. “But in the last three years, we’ve seen a pretty big shift away from just doing digital marketing—though it’s still very important—to looking at how technology can help enhance patient outcomes.”

Today’s beyond-the-pill solutions can collect, monitor and analyze health-related information, track patient activity, improve medication adherence, provide personalized decision support, predict medical crises and streamline medical care using a variety of advanced computing techniques. Mobile technology, the IoT and AI are three of the technologies making this possible.

Read one here

 

 

Save

rob halkes's curator insight, January 7, 2017 9:33 AM

Pharma started about thinking in terms of servicing health care "beyond the pill" in about 2000. Today developments have been increased by ideas of 'integrated care' and "precision medicine" the latest concept indicates fine tuning of medications to personal physical and genome conditions. Diagnostics are all in the game, that is. But a study in which I participated [ http://1.eyeforpharma.com/LP=5676 ] made clear that development and creation is one, servicing and delivering is two. Partnerships for example are unavoidable is one in in the game for sustainable business.

The World's Most Reputable Pharmaceutical Companies In 2016

From www.forbes.com

Like in most industries, players in the pharmaceutical world get a boost when customers the world over feel that they are innovators, act responsibly and are, generally speaking, a force for good. Recently a survey was published scoring exactly how good people in developed countries all over the world feel about big pharma.
rob halkes's curator insight, December 27, 2016 11:20 AM

Just discovered the global pharma reputation ranking by the Reputation Institute. Based on 7 dimensions of reputation, defined by the institute, the companies were evaluated by respondents around the world. These were "Products&Services, Innovation, Workplace,Governance, Citizenship, Leadership and Performance". See the RepTrak Institute here

PatientView however has studied the global reputation of pharma companies in the perspective of patients and patient groups since 2011! See here.  Their respondents were also distinguished by those who state to be familiar with a company and  those who really worked with a company, which generates interesting data! PatientView is now preparing data such that companies can retrieve their bespoke ranking data to see how their reputation in the perspective of patients can further be improved

Pharma Guy's curator insight, January 2, 2017 10:27 AM

NOTE: One trend pharmaceutical companies should take note of is the tendency of respondents to be uninformed or neutral about what companies actually do in certain areas. According to the survey, 12% of respondents did not have knowledge or opinion about the companies’ overall performance. Meanwhile, 11% had no knowledge of companies’ citizenship activities (promoting good causes and protecting the environment) and 14% didn’t know anything about the workplaces of the firms they were asked to score.

The Hard Truth About Business Model Innovation

From sloanreview.mit.edu

Successful business model innovation requires an understanding of how business models evolve.

Many attempts at business model innovation fail. To change that, executives need to understand how business models develop through predictable stages over time — and then apply that understanding to key decisions about new business models.

Understanding the interdependencies in a business model is important because those interdependencies grow and harden across time, creating another fundamental truth that is critical for leaders to understand: Business models by their very nature are designed not to change, and they become less flexible and more resistant to change as they develop over time. Leaders of the world’s best businesses should take special note, because the better your business model performs at its assigned task, the more interdependent and less capable of change it likely is. The strengthening of these interdependencies is not an intentional act by managers; rather, it comes from the emergence of processes that arise as the natural, collective response to recurrent activities. The longer a business unit exists, the more often it will confront similar problems and the more ingrained its approaches to solving those problems will become. We often refer to these ingrained approaches as a business’s “culture.”

 

rob halkes's curator insight, September 14, 2016 10:25 AM

Great article about business model innovation. I was struck by the resemblances of errors made at introducing new value added services to pharmaceuticals, "beyond the pill". The same may possibly be expected by the new "hype" (?) about patient centricity: in my mind doing things without reflection about what it is: ending up in webinars/conferences existing mainly of either pharma staff in which they share their ignorance, or even in pharma staff added with a patient or patient representative, in which the patient is commonly canonized (as in 'sainted'): understandable but not a functional way of developing new trends in a company, let alone a new trend in a business sector..

See here what patients really have to say about corporate pharma companies and its patient "centricity": PatientView.com

What pharma digital marketers need to know about Google's mobile search change

From odonnellonline.ie

Google has announced changes to how it will rank sites in mobile search, penalising some websites. Here's what pharma digital marketers need to know.
No comment yet.

Beyond fitness apps: patient-centric mobile health 

From pharmaphorum.com

mHealth brings opportunities to better understand how conditions impact everyday life and develop solutions that work.
Nilambari Mane's curator insight, August 17, 2016 11:05 AM
Interesting read on how patient-centric apps are gaining momentum and present great business opportunities for Pharma Companies.  

IBM, Pfizer launch joint experiment to help measure Parkinson’s symptoms using IoT and analytics

From techcrunch.com

IBM, Pfizer launch joint experiment to help measure Parkinson’s symptoms using IoT and analytics
No comment yet.

CONSULTER LE PROGRAMME DU #FCSante !

From emailing.web-overcome.net

CONSULTER LE PROGRAMME DU #FCSante ! Ne manquez pas cette journée de conférences le vendredi 27 novembre ! Vous souhaitez y assister ? Inscrivez-vous ! Vous avez -30 ans ou êtes étudiant ?
NOUVEAUTÉ : TARIF SPÉCIAL
Inscrivez-vous !   09h00 Ouverture du Festival et accueil des participants 11h00 Ouverture par Dominique Noël, Présidente du Festival de la Communication Santé 11h15
12h15 

L’EXPRESSION DU PATIENT, COMPOSANTE CLÉ DE SA LUTTE CONTRE LA MALADIE ?
En partenariat avec les entreprises du Médicament (Leem)

   Plusieurs expériences pilotes sont lancées en France. La parole des patients participe au renouveau du parcours de soins.
Animée par Éric de Branche, Directeur de la Communication - Leem
• Isabelle Delattre, Créatrice des prix Paroles de Patients et Talents de Patients
• Marine de Nicola, Chanteuse et "survivante" du cancer
• Georges Elia Sarfati, Professeur des Universités, analyste existentiel, philosophe et linguiste
• Alain Toledano, Oncologue et Radiothérapeute
• Pr Catherine Tourette-Turgis, Fondatrice de l’Université des Patients, Faculté de Médecine, Université Pierre et Marie Curie (Paris) 12h15 - 14h00 Déjeuner - networking 14h00
14h05 SPEED VISION : RÉSEAUX SOCIAUX ET SANTÉ... CE QUE SHAKESPEARE PEUT NOUS APPRENDRE
Lionel Reichardt, Fondateur de Pharmageek 14h05
15h05 

LES NOUVELLES RELATIONS PATIENTS… DE LA MARQUE ENTREPRISE À LA MARQUE MÉDIA-SANTÉ
En partenariat avec la Fédération Nationale de l’Information Médicale (FNIM)

   À l’heure du patient centric, les entreprises de santé doivent-elles devenir des marques média et redéfinir leur communication auprès du patient-consommateur de santé ?
Animée par Éric Phélippeau, Président de la FNIM
• Nadia Auzanneau, Directrice d’OpinionWay Santé, dévoilera en avant-première les chiffres clés de l’enquête réalisée en partenariat avec la FNIM / FCS
• Valérie Perruchot Garcia, Directeur des Affaires Publiques et de la Communication - Janssen France
• Sébastien Sillon, Directeur de la Communication, Mécénat et RSE - Laboratoires Expanscience
• Isabelle Morin, Directeur Marketing et Communication - Biogaran 15h05
15h10 SPEED VISION : LES 3 ENJEUX CLÉS DU BIG DATA EN SANTÉ ?
Emmanuelle Pierga, Directrice de la Communication d’Orange Healthcare
David Réguer, Directeur de RCA Factory Healthcare 15h10
16h10 

ENVIRONNEMENT ET SANTÉ : DES LIENS D’INTÉRÊT À NE PLUS IGNORER
En partenariat avec Pharmaceutiques

   En miroir de la conférence mondiale sur le climat tenue à Paris en décembre, Pharmaceutiques organise une table ronde sur l’impact des problématiques environnementales en matière de santé. Effets du climat et de la pollution sur l’état sanitaire des populations, incidence environnementale des activités de production des soins, responsabilité sociale et environnementale des entreprises de santé, gestion des déchets à risque… diverses questions seront abordées.
Animée par Hervé Réquillart, Directeur de la Rédaction - Pharmaceutiques
• Delphine Caroff, Directeur des Affaires Européennes, relations extérieures et RSE - Leem
• Béatrice Parance, Professeur agrégée de droit privé, Université Paris 8 Vincennes - Saint-Denis
• Philippe Le Jeunne, Directeur Médical - IMS Health France 16h10
16h15 SPEED VISION : HUMANISME ET NOUVELLES TECHNOLOGIES : OXYMORE OU SYNERGIE ?
Cécile Monteil, Directeur Médical à Ad Scientiam, Fondatrice d’Eppocrate, Docteur, Hôpital Robert Debré (Paris) 16h15 - 16h45 Pause - networking 16h45
16h50 SPEED VISION : LE MÉDECIN ET LE GEEK... REGARDS CROISÉS SUR LA SANTÉ CONNECTÉE
Les dernières innovations d’objets connectés santé
Lionel Reichardt, Fondateur de Pharmageek
Cécile Monteil, Directeur Médical à Ad Scientiam, Fondatrice d’Eppocrate, Docteur, Hôpital Robert Debré (Paris) 16h50
17h50 

LE SYSTÈME DE SANTÉ EST-IL EN DANGER ?
En partenariat avec Réseau Communication Santé (RCS)

   Animée par Jérôme Vincent, Journaliste Le Point
• Pr André Grimaldi, Professeur Émérite d’Endocrinologie-Diabétologie, CHU de La Pitié - Salpêtrière (Paris)
• Christophe Jacquinet, Président - Santéliance Conseil 17h50
18h00 

CONCLUSION DE LA JOURNÉE
Synthèse de la journée par les étudiants du Master Marketing Pharmaceutique de la Faculté de Pharmacie de Chatenay-Malabry

 

19h00 Cocktail

20h00 Dîner

 Vous souhaitez y assister ? Inscrivez-vous ! Vous avez -30 ans ou êtes étudiant ?
NOUVEAUTÉ : TARIF SPÉCIAL
Inscrivez-vous ! 

Et n’oubliez pas, il est encore temps de soumettre vos plus belles campagnes !

Communication santé publiqueCommunication produit grand publicCommunication médicaleCommunication hospitalièreCommunication associativeCommunication patients et leurs aidantsCommunication corporateCommunication santé en entrepriseStart-up 

Vous êtes prêt à relever le défi ?
Inscrivez-vous !

 

No comment yet.

5 Reasons Pharma Should Care About Apple Watch

From the-earthworks.com

For months and months speculation was rife about the Apple Watch (or iWatch as was the expected moniker) and the possible implications and applications for healthcare. Then we had the 9th March launch event in San Francisco and theApple Watch seemed to sink like a lead balloon in the minds of health technology enthusiasts. This was aided by articles such as the one in the Wall Street Journal that claimed much of the exciting health sensor technology had been scrapped and asked: What Exactly Is an Apple Watch For? (Subscription required)

 

I believe that technology only becomes socially interesting when it becomes technologically boring. We can only really impact health at scale when we utilise technology that has true mainstream reach. However I feel there are still a number of key reasons the Apple Watch is worth thinking about for healthcare broadly, and pharmaceutical companies specifically. Here are five reasons pharma should care as we approach the April 24th Apple Watch launch date

Jennifer Grech's curator insight, April 7, 2015 5:57 AM

Are we (pharma) listening?

INTERVIEW: Accenture's David Logue talks digital pharma

From pharmatimes.com

INTERVIEW: Accenture's David Logue talks digital pharma
PharmaTimes
DL: Pharma marketing organisations are often set up with a dependency on colleagues in the technology function to deliver digital experiences.
No comment yet.

Janssen lance un outil interactif sur les maladies les plus répandues en Europe MyPharma Editions | L'Info Industrie & Politique de Santé

From www.mypharma-editions.com

A l'occasion de la Journée mondiale de la tuberculose, le Janssen Health Policy Centre a dévoilé mardi un tableau de bord numérique permettant de parcourir et de comparer les données sanitaires de 15 maladies parmi les plus répandues dans les 28 États membres de l'Union Européenne (UE), un outil d'analyse unique en son genre.
No comment yet.

Few seniors trust pharma company-sponsored sites. Can Pharma Sites Cure Seniors' Lack of Trust? - eMarketer

From www.emarketer.com

When it comes to researching diseases, seniors don't turn to—or trust—pharmaceutical companies very much. If pharma companies want to change this, they'll need seniors' doctors, friends and family members to sing their praises, as recommendations are the top factors that would motivate those 66 and older to visit pharma-sponsored websites.
Alexandre Gultzgoff's curator insight, March 26, 2015 9:14 AM

voices of senior customers matter also...

Sanofi accélère dans l’e-santé #hcsmeufr

From www.lesechos.fr

Sanofi a entamé le recrutement de 700 patients diabétiques pour tester une application leur permettant de calculer en temps réel leur dose...
No comment yet.

Searching social networks to detect adverse reactions

From advertisinghealth.co.uk

Up to 90% of side effects to drugs are not reported, according to some estimates. “Adverse drug reactions (ADRs) are grossly under reported by everyone, including healthcare professionals, but particularly so by patients,” says David Lewis, head of global safety at Novartis, who is co-ordinating the involvement of pharmaceutical companies in a €2.3m three-year public-private project called Web-RADR (Recognising Adverse Drug Reactions).

Marie Ennis-O'Connor's curator insight, March 16, 2015 8:37 AM

Ethical implications of data mining by pharma?

Pharma Guy's curator insight, March 17, 2015 8:27 AM


The use of smartphone technology and social media for gathering information on suspected adverse drug reactions (ADRs) is to be evaluated by a new European consortium.


WEB-RADR's founding members include pharma, academics and European medicines regulators like the UK's MHRA and it is funded through the Innovative Medicines Initiative - a partnership between the EC and EFPIA.


The three-year project's goals include developing a mobile app for healthcare professionals and the public to report suspected ADRs to national EU regulators and investigating the potential for publicly available social media data to be used for identifying potential drug safety issues.


WEB-RADR will also make a series of recommendations on how smartphone and social media should be used ethically and scientifically for international drug safety monitoring.

Pharma Marketing Blog: Healthcare Marketers Trend Report 2014: I Give It a "C-Meh!" Rating

From pharmamkting.blogspot.nl

Not all available market research is created equal," says Rich Meyer, author of DTC Marketing Blog. According to Meyer, "some research is a must have and provides insights, but there is also a lot of available research that doesn’t clarify findings and is written by journalists not people will real world pharma business experience." He goes on to rate various sources of pharma marketing research (here).

Meyer has two ratings:"A-Must Have" and "D-Pass," which means don't bother with it. Meyer doesn't have a "C-Meh!" rating -- that's my way of saying "lackluster, take it or leave it."

One study "written by journalists" is the MM&M/Ogilvy CommonHealth Healthcare Marketers Trend Report, the 2014 version of which was just published (here). Let me tell you why I give it a "C-Meh!" rating.

One surprising finding of this survey of 202 "qualified" senior executives -- "all director level and above" -- employed by pharmaceutical, biotechnology, devices and diagnostics companies, is that 22% of pharma marketing budgets of these individuals goes to some form of digital marketing (websites, digital ads, SEO marketing, and social media).


See further read on blog!

rob halkes's curator insight, June 3, 2014 7:39 AM

Great review  by John Mack, @pharmaguy of these trend "researches". Due to his investment in time, we can state: trend reports? "C-meh" ;-)


80% of doctors in China use a smartphone - PMLiVE

From www.pmlive.com

Doctors in China are making strong use of smartphones for professional purposes, according to a new report.

The Manhattan Research Study from Decision Resources Group found that 80 per cent of physicians in the country now own or use one of the devices.

The analysts said in the topline figures they released that smartphone use covers a variety of activities and that consequently pharma marketers must tailor their approach when developing smartphone content aimed at doctors in China.

The figures put the country on a par with the US, where doctors' use of smartphones – through growing rapidly over the last few years – seems to have plateaued.

Meanwhile, the detail that Decision Resources shared from its Taking the Pulse Global 2014 report also showed that doctors in Brazil don't think pharma is making the best use of tablet detailing.

Three quarters of the doctors in Brazil surveyed said they had seen a tablet-wielding rep in 2014 but Decision Resources said satisfaction rates with the technology remains relatively low.

“Content and user-experience need to improve in order to enhance tablet-rep campaigns and increase physician satisfaction,” the analysts concluded.

Meredith Ressi, VP of marketing innovation solutions at Decision Resources, said: “Many companies now centralise digital best practices through global centers of excellence, while also giving local affiliates the flexibility to tweak their approach and asset mix to suit local market demand.

“These findings highlight the necessity of this tailored approach and can help multinational companies inform these priorities by market.”

rob halkes's curator insight, May 16, 2014 10:22 AM

It is still a lot about promotional effort. Surely, a baseline, but what about interaction and communication - it is difficult isn't it?

See how the process of development could be:

http://www.slideshare.net/ARJHalk/edetailing-the-core-to-new-commercial-approach-web

Boehringer plans to open trial data back to 1998 - PMLiVE

From www.pmlive.com

Boehringer Ingelheim has announced that it intends to make drug data from clinical trials stemming back to 1998 accessible as part of efforts to improve research transparency within the industry.

The move is part of a collaboration with fellow pharma companies Sanofi, GlaxoSmithKline, Novartis, Roche and ViiV Healthcare on an online platform to handle requests from researchers for trial data.

Boehringer's chairman Dr Andreas Barner made the announcement at Boehringer's annual company meeting yesterday, following up from a commitment to transparency announced at the same meeting in 2013.

Dr Barner, who also heads R&D at Boehringer, explained that the online platform - available at clinicalstudydatarequest.com - currently contained 50 trials available for which to request patient-level data, but the plan is to reach 500 from all involved parties.

“That's quite a job to achieve. but we have to do it in interest of what data and information can be shared with others,” said Dr Barner.

“We have always argued in favour of transparency and now want a more scientific discussion on the level of trial data and have therefore joined up with several research-based pharmaceutical companies in order to make clinical trials data and documents available to a wider public.” ....

read on in the original post here

rob halkes's curator insight, April 22, 2014 4:46 AM

Great to see real development in sharing clinical research data!

Value in Pharmaceutical Pricing | OECD iLibrary

From www.oecd-ilibrary.org

Abstract

This study analyses how 14 OECD Countries refer to “value” when making decisions on reimbursement and prices of new medicines. It details the type of outcomes considered, the perspective and methods adopted for economic evaluation when used; and the consideration of budget impact. It describes which dimensions are taken into account in the assessment of “innovativeness” and the consequences of this assessment on prices; it confirms that treatments for severe and/or rare diseases are often more valued than others and shows how countries use product-specific agreements in an attempt to better align value and price.

..

Conclusions

 

The main objective of this report was to explore value-based pricing for pharmaceuticals. In principle, value-based pricing (VBP) can offer better value-for-money for purchasers of pharmaceuticals. It also gives clear signals to pharmaceutical companies that they will be rewarded if their products address the priorities of the purchasers, so in the longer run may reorient pharmaceutical innovation in a more cost- effective direction. However, it is easier to talk of rewarding ‘value’ than it is actually to do so. Is it value to the purchaser that should be the basis of decisions (i.e. some combination of the increase in health and the reduction in other health spending) or the value to society (which would also take into account increased labour force productivity of those who are less sick and those who no longer care for others, amongst other things)? Is there ‘value’ in innovation itself? Countries which use value-based pricing for pharmaceuticals do not make the same choices as to how to determine value. Furthermore, countries which do not have value-based pricing per se may take into account some of the elements used in economic assessments of value in making their decisions. This report attempts to shed light on what impact these different choices make to reimbursement decisions and prices.

...

Read on in the downloadable PDF!

 

Please cite this paper as:

 

Paris, V. and A. Belloni (2013), “Value in Pharmaceutical Pricing”,

 

OECD Health Working Papers, No. 63, OECD Publishing.

 

http://dx.doi.org/10.1787/5k43jc9v6knx-en

 

rob halkes's curator insight, April 16, 2014 5:36 AM

Very insightful research!

Just for your appetite, I quote two relevant conclusions:

  • The first, and by no means trivial, conclusion is that the type of health outcomes considered by assessment bodies and decision-makers to inform or make decisions on reimbursement seem to have more in common with each other than differences. (p.58)

  • One substantial difference between the case-study countries is whether they take into account utility for patients as a measure of outcome. Typically, countries using economic evaluation consider utility (Australia, Canada, Sweden, Norway and the United Kingdom) while other countries (e.g. France or Italy) do not. This is expected to have an impact on reimbursement decisions, price levels and relative prices of different categories of products. From the sample of countries and products scrutinized, it was not possible to identify such an impact.(p.58)